Tumor cell–Natural Killer cell interface (NK-Tumor Synapse)

The tumor cell–Natural Killer (NK) cell interface, also known as the immunological synapse, is the specialized, dynamic contact area where an NK cell interacts with a potential target cell to determine its fate (Orange, J. S., 2008, Nature Reviews Immunology). This interface is governed by a complex rheostat of signals from activating receptors, such as NKG2D and CD16, and inhibitory receptors, such as Killer-cell Immunoglobulin-like Receptors (KIRs) and NKG2A (Long, E. O., et al., 2013, Annual Review of Immunology). In cancer, tumor cells often evade immune detection by altering the expression of ligands at this interface, such as downregulating MHC class I or upregulating inhibitory ligands like HLA-E (André, P., et al., 2018, Cell). Therapeutic strategies aim to manipulate this interface to restore NK cell cytotoxicity, primarily through the use of checkpoint inhibitors like monalizumab or by facilitating antibody-dependent cellular cytotoxicity (ADCC) with monoclonal antibodies like rituximab (Wang, W., et al., 2015, Frontiers in Immunology). Understanding the molecular architecture and signaling dynamics of this interface is essential for the development of next-generation immunotherapies, including bispecific NK-cell engagers (BiKEs) and CAR-NK cells (Shimasaki, N., et al., 2020, Nature Reviews Drug Discovery).

Other names

NK cell immunological synapseNK-tumor interfaceNK cell-target cell contactNK-IS

Modulation of the immunological synapse through checkpoint inhibition (e.g., NKG2A, KIR) or enhancement of activating signals via antibody-dependent cellular cytotoxicity (ADCC).